Your browser doesn't support javascript.
loading
Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment.
Mirza, Amar N; Fry, Micah A; Urman, Nicole M; Atwood, Scott X; Roffey, Jon; Ott, Gregory R; Chen, Bin; Lee, Alex; Brown, Alexander S; Aasi, Sumaira Z; Hollmig, Tyler; Ator, Mark A; Dorsey, Bruce D; Ruggeri, Bruce R; Zificsak, Craig A; Sirota, Marina; Tang, Jean Y; Butte, Atul; Epstein, Ervin; Sarin, Kavita Y; Oro, Anthony E.
Afiliação
  • Mirza AN; Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA.
  • Fry MA; Children's Hospital Oakland Research Institute, Oakland, California, USA.
  • Urman NM; Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA.
  • Atwood SX; Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA.
  • Roffey J; CRUK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre, London, United Kingdom.
  • Ott GR; Teva Branded Pharmaceutical Products R&D, West Chester, Pennsylvania, USA.
  • Chen B; Institute for Computational Health Sciences, UCSF, San Francisco, California, USA.
  • Lee A; Children's Hospital Oakland Research Institute, Oakland, California, USA.
  • Brown AS; Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA.
  • Aasi SZ; Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA.
  • Hollmig T; Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA.
  • Ator MA; Teva Branded Pharmaceutical Products R&D, West Chester, Pennsylvania, USA.
  • Dorsey BD; Teva Branded Pharmaceutical Products R&D, West Chester, Pennsylvania, USA.
  • Ruggeri BR; Teva Branded Pharmaceutical Products R&D, West Chester, Pennsylvania, USA.
  • Zificsak CA; Teva Branded Pharmaceutical Products R&D, West Chester, Pennsylvania, USA.
  • Sirota M; Institute for Computational Health Sciences, UCSF, San Francisco, California, USA.
  • Tang JY; Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA.
  • Butte A; Children's Hospital Oakland Research Institute, Oakland, California, USA.
  • Epstein E; Institute for Computational Health Sciences, UCSF, San Francisco, California, USA.
  • Sarin KY; Children's Hospital Oakland Research Institute, Oakland, California, USA.
  • Oro AE; Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA.
JCI Insight ; 2(21)2017 11 02.
Article em En | MEDLINE | ID: mdl-29093271
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Proteína Quinase C / Carcinoma Basocelular / Histona Desacetilase 1 / Inibidores de Histona Desacetilases / Isoenzimas Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: JCI Insight Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Proteína Quinase C / Carcinoma Basocelular / Histona Desacetilase 1 / Inibidores de Histona Desacetilases / Isoenzimas Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: JCI Insight Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos